Entrada's mission is to treat devastating diseases with intracellular biologics

"At Entrada, we value intellectual curiosity and enjoy the challenge of fighting the good fight: waking up each day to advance our science one step closer to helping patients and their caregivers who deserve better treatments."

Dipal Doshi, President and Chief Executive Officer

Novel Platform, Growing Intracellular Biologics Pipeline

Entrada’s Endosomal Escape Vehicle (EEV™) technology represents a fundamental advancement to the design and development of intracellular biologics. Our therapeutic candidates exhibit high cellular uptake, achieve highly efficient endosomal escape and are designed to be exquisitely specific to intracellular targets.

Our novel approach addresses challenges associated with current therapeutics and allows us to engage targets previously considered inaccessible and undruggable. Explore our platform and discover our pipeline.


Dipal Doshi

President and Chief Executive Officer

Natarajan Sethuraman, PhD

Chief Scientific Officer

Nerissa C. Kreher, MD

Chief Medical Officer

Nathan J. Dowden

Chief Operating Officer

Kory Wentworth, CPA

Chief Financial Officer

Kerry Robert

Head of Human Resources

Jared Cohen, PhD, JD

Vice President, Head of Intellectual Property & Legal Affairs

Karla MacDonald

Vice President, Corporate Communications

Board of Directors

Dipal Doshi

President and Chief Executive Officer

Kush M. Parmar, MD, PhD

Managing Partner, 5AM Ventures (Board Chairman)

Todd Foley

Managing Director,
MPM Capital

Carole Nuechterlein, JD

Head, Roche Venture Fund

John F. Crowley

Chairman and CEO, Amicus Therapeutics

Peter S. Kim, PhD

Virginia & D.K. Ludwig Professor of Biochemistry, Stanford University

Mary Thistle

Special Advisor, Bill & Melinda Gates Medical Research Institute